Spontaneous regression of metastases from melanoma: review of the literature.

abstract：:Cutaneous melanoma is one of the most lethal cancers because of its increased rate of metastasis and resistance to available therapeutic options. Early studies indicate that metformin has beneficial effects on some types of cancer, including melanoma. To clarify knowledge of the mechanism of action of metformin on thi...

journal_title：Melanoma research

authors： de Souza Neto FP,Bernardes SS,Marinello PC,Melo GP,Luiz RC,Cecchini R,Cecchini AL

更新日期：2017-12-01 00:00:00

abstract：:Lysosome-associated membrane protein-1 is a protein with a significant content of beta1,6-branched N-glycans. It is thought that enhanced expression of lysosome-associated membrane protein-1 in tumour cells may promote invasion by influencing both adhesion to extracellular matrix and perhaps also binding to endothelia...

journal_title：Melanoma research

authors： Kuźbicki L,Gajo B,Chwirot BW

更新日期：2006-06-01 00:00:00

abstract：:Microphthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. We previously reported that Mitf expression, as detected by immunohistochemical analysis, is an independent prognostic marker in patients with intermediate-thickness melanoma. However, the clinical significance of Mit...

journal_title：Melanoma research

authors： Naffouje S,Naffouje R,Bhagwandin S,Salti GI

更新日期：2015-12-01 00:00:00

abstract：:Checkpoint inhibitor immunotherapy is a transformative treatment for advanced malignancies, but can be associated with numerous immune-related adverse events (irAEs). The majority of irAEs include those that closely resemble known cutaneous and neurocutaneous autoimmune or autoinflammatory diseases, such as scleroderm...

journal_title：Melanoma research

authors： Kosche C,Stout M,Sosman J,Lukas RV,Choi JN

更新日期：2020-06-01 00:00:00

abstract：:One of the principal applications of tumour markers is the early detection of recurrent disease in the follow-up of patients. In the study described here, we compared the usefulness of two serum markers for melanoma, 5-S-cysteinyldopa (5-S-CD) and melanoma inhibitory activity (MIA), in the monitoring of postsurgical m...

journal_title：Melanoma research

authors： Matsushita Y,Hatta N,Wakamatsu K,Takehara K,Ito S,Takata M

更新日期：2002-08-01 00:00:00

abstract：:Malignant melanoma is a cancer whose incidence is rising rapidly. Extensive studies of primary tumors and tumor-derived cell lines revealed that inappropriate activation of signal transducer and activator of transcription (STAT) proteins, particularly of STAT3 and 5, occurs with high frequency in various human cancers...

journal_title：Melanoma research

authors： Hassel JC,Winnemöller D,Schartl M,Wellbrock C

更新日期：2008-12-01 00:00:00

abstract：:Malignant melanoma is not only one of the most aggressive and lethal types of neoplasm, but its incidence in the general population is currently increasing at an alarming pace. It is interesting that most melanomas retain many of their characteristics of differentiation, including a dendritic nature and the production...

journal_title：Melanoma research

authors： Tsukamoto K,Gersten DM,Law LW,Hearing VJ

更新日期：1991-11-01 00:00:00

abstract：:Sentinel lymph node dissection (SLND) identifies melanoma patients with metastatic disease who would benefit from radical lymph node dissection (RLND). Rarely, patients with melanoma have an underlying lymphoproliferative disease, and melanoma metastases might develop as collision tumours in the sentinel lymph node (S...

journal_title：Melanoma research

authors： Gero D,Queiros da Mota V,Boubaker A,Berthod G,de Leval L,Demartines N,Matter M

更新日期：2014-08-01 00:00:00

abstract：:Single-agent anti-PD1 antibodies are usually very well tolerated, but serious toxicity can still occur. Despite the PD-1 pathway seems to be relevant in the pathogenesis of immune-related myositis, anti-PD1-related myositis is generally a rare side effect of the treatment and usually not serious. However, its frequenc...

journal_title：Melanoma research

authors： Liu WK,Naban N,Kaul A,Patel N,Fusi A

更新日期：2021-02-01 00:00:00

abstract：:Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-alpha (IFNalpha) as single drugs, or in combination, results in a response rate of approximately 15-20%. This study evaluated the activity and toxicity following treatment with a combination of DTIC, IFNalpha2b and verapamil (V...

journal_title：Melanoma research

authors： Andersson R,Ake Hofer P,Riklund-Ahlström K,Henriksson R

更新日期：2003-02-01 00:00:00

abstract：:Despite the general advances in the chemotherapy of malignancies, progress comes slow in the management of patients with disseminated melanoma. Unreflected enthusiasm and frustrated scepticism are the scylla and charybdis between which the physician tries to choose the right way. ...

journal_title：Melanoma research

authors： Kleeberg UR

更新日期：1997-08-01 00:00:00

abstract：:The growth rate (GR) of melanomas is not uniform. A fast-growing subtype has been identified and seems to have a role in the stabilization of the mortality rates because of melanoma. To examine features associated with fast-growing melanomas (FGMs) and to determine the relationship between the GR and well-recognized p...

journal_title：Melanoma research

authors： Martorell-Calatayud A,Nagore E,Botella-Estrada R,Scherer D,Requena C,Serra-Guillén C,Llombart B,Sanmartin O,Kumar R,Guillén C

更新日期：2011-04-01 00:00:00

abstract：:Melanoma cells are unusual because, unlike most epithelial tumours, constitutive expression of HLA class II antigens is common. We have previously demonstrated that a peptide-specific CD4+ T-cell clone proliferates briskly in response to peptide and HLA class II expressing melanoma cell lines derived from metastases. ...

journal_title：Melanoma research

authors： Brady MS,Eckels DD,Lee F,Ree SY,Lee JS

更新日期：1999-04-01 00:00:00

abstract：:The correlation between ultraviolet radiation of the skin and melanoma incidence in humans is well established. Interestingly, epidemiologic data suggest also a correlation to an increased BMI pointing to metabolic trigger factors in melanoma pathogenesis. To substantiate this connection, we studied the expression of ...

journal_title：Melanoma research

authors： Kleemann J,Hrgovic I,Ter-Nedden J,Kleimann P,Steinhorst K,Härle K,Müller J,Kaufmann R,Meissner M,Kippenberger S

更新日期：2018-08-01 00:00:00

abstract：:Paraffin-embedded tissue from the primary tumours of 116 patients with malignant melanoma, and in 40 cases also from corresponding metastases, were examined for accumulation of p53 protein. The fraction of tumours with positive p53 immunostaining was 13% in the least invasive and 36% in the most invasive primary lesio...

journal_title：Melanoma research

authors： Flørenes VA,Holm R,Fodstad O

更新日期：1995-06-01 00:00:00

abstract：:Before licensing, ipilimumab was first made available to previously treated advanced melanoma patients through an expanded access programme (EAP) across Europe. We interrogated data from UK EAP patients to inform future clinical practice. Clinicians registered in the UK EAP provided anonymized patient data using a pre...

journal_title：Melanoma research

authors： Ahmad SS,Qian W,Ellis S,Mason E,Khattak MA,Gupta A,Shaw H,Quinton A,Kovarikova J,Thillai K,Rao A,Board R,Nobes J,Dalgleish A,Grumett S,Maraveyas A,Danson S,Talbot T,Harries M,Marples M,Plummer R,Kumar S,Nathan

更新日期：2015-10-01 00:00:00

abstract：:Cell free extracts from metastases of human melanoma contain a highly active ribonucleoside diphosphate reductase (RR) which uses guanosine diphosphate (GDP) as substrate and deoxythymidine triphosphate (dTTP) as effector. No activity could be detected in these extracts when cytidine diphosphate (CDP) was used as the ...

journal_title：Melanoma research

authors： Schallreuter KU,Elgren TE,Nelson LS Jr,MacFarlan S,Yan-Sze I,Hogenkamp HP

更新日期：1992-12-01 00:00:00

abstract：:In metastatic melanoma (MM) immunomodulating agents, such as interleukin-2 (IL-2) and interferon-α (IFN-α), have shown therapeutic benefit as they enhance antitumor immune response. Considering tumor-induced suppression of natural killer (NK) cell activity, it is of interest to study the affect of these cytokines on t...

journal_title：Melanoma research

authors： Konjević G,Mirjačić Martinović K,Vuletić A,Babović N

更新日期：2010-12-01 00:00:00

abstract：:When cancer cells, including melanoma cells, are genetically altered to secrete cytokines, irradiated and injected into subjects, long-term antitumour immunity is induced. Optimally, existing melanomas induced to produce cytokines in vivo could stimulate this same immune response. Although in vivo electroporation enha...

journal_title：Melanoma research

authors： Heller L,Pottinger C,Jaroszeski MJ,Gilbert R,Heller R

更新日期：2000-12-01 00:00:00

abstract：:The CD10 antigen is a neutral endopeptidase expressed by a variety of mesenchymal tumours (haemopoietic or not), including a subset of malignant melanomas. We investigated the expression of CD10 in formalin-fixed, paraffin-embedded tissue specimens of 72 cutaneous melanomas (28 primary, 26 metastatic to the skin and 1...

journal_title：Melanoma research

authors： Kanitakis J,Narvaez D,Claudy A

更新日期：2002-06-01 00:00:00

abstract：:In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and the response rate in chemotherapy-naive patients with advanced melano...

journal_title：Melanoma research

authors： Bedikian AY,Garbe C,Conry R,Lebbe C,Grob JJ,Genasense Melanoma Study Group.

更新日期：2014-06-01 00:00:00

abstract：:Selective sentinel lymph node (SLN) dissection is widely used in the management of cutaneous melanoma patients without clinical evidence of nodal metastases. A series of 274 consecutive melanoma patients who underwent melanoma primary excision and SLN mapping at our institutions since 1998, and were thereafter followe...

journal_title：Melanoma research

authors： Macripò G,Quaglino P,Caliendo V,Ronco AM,Soltani S,Giacone E,Pau S,Fierro MT,Bernengo MG

更新日期：2004-04-01 00:00:00

abstract：:Conjunctival melanoma is a rare disease, and little is known about its molecular background. Here, we present the case of a 48-year-old patient with conjunctival melanoma and metachronic lymph node and skin metastasis with KRAS p.K117Y mutation in exon 4 in all the lesions. The cancer genome interpreter predicted this...

journal_title：Melanoma research

authors： Del Carpio Huerta LP,Mas Castells M,Anguera Palacios G,Sullivan I,Gonzalez Vidal A,Majem Tarruella M

更新日期：2018-04-01 00:00:00

abstract：:Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations - BRAF A598_T599insV and V60...

journal_title：Melanoma research

authors： Rogiers A,Vander Borght S,Tuand K,Wolter P,Stas M,Boecxstaens V,Garmyn M,van den Oord JJ,Vandenberghe P,Bechter O

更新日期：2017-10-01 00:00:00

abstract：:Results obtained using a computerized image analysis system as an aid to clinical diagnosis of melanoma are reported. The system comprises a colour television camera connected through a digitizing board to a 386 personal computer. By means of original algorithms able to measure the shape, the colours and texture of a ...

journal_title：Melanoma research

authors： Cascinelli N,Ferrario M,Bufalino R,Zurrida S,Galimberti V,Mascheroni L,Bartoli C,Clemente C

更新日期：1992-09-01 00:00:00

abstract：:Little population-based data has been published about skin cancers in children and young adults. In this study, 200 cases of melanoma and non-melanoma skin cancers diagnosed under 25 years of age in the North of England from 1968-1995 were obtained from the Northern Region Young Persons' Malignant Disease Registry. Th...

journal_title：Melanoma research

authors： Pearce MS,Parker L,Cotterill SJ,Gordon PM,Craft AW

更新日期：2003-08-01 00:00:00

abstract：:High-dose cisplatin regimens have been shown to be highly active in advanced melanoma patients but are associated with unacceptable side effects. In order to increase the platinum dose but avoid severe side effects, we treated 15 dacarbazine (DTIC)-resistant metastatic melanoma patients with a combination regimen of c...

journal_title：Melanoma research

authors： Güven K,Kittler H,Wolff K,Pehamberger H

更新日期：2001-08-01 00:00:00

abstract：:Ipilimumab (anti-CTLA-4 antibody) is a new tool for the treatment of metastatic melanoma patients that has led to an improvement in survival rates worldwide. New types of toxicities have been described with ipilimumab called 'immune-related adverse events' or irAEs. Here, we report an acute and steroid resistant case ...

journal_title：Melanoma research

authors： Pagès C,Gornet JM,Monsel G,Allez M,Bertheau P,Bagot M,Lebbé C,Viguier M

更新日期：2013-06-01 00:00:00

abstract：:Recently, we reported on the associations of seven single nucleotide polymorphisms (SNPs) in the promoter region of MMP1 gene with susceptibility to cutaneous melanoma (CM). Considering the reported correlation between MMP1 expression and melanoma progression, we hypothesized that these promoter SNPs might affect CM p...

journal_title：Melanoma research

authors： Liu H,Wei Q,Gershenwald JE,Prieto VG,Lee JE,Duvic M,Grimm EA,Wang LE

更新日期：2012-04-01 00:00:00

abstract：:The proto-oncogene c-Kit encodes a membrane receptor protein with intrinsic tyrosine kinase activity. Activation of c-Kit induces cell proliferation, differentiation or migration among different cell types. The present study provides evidence that c-Kit plays an important role in the cell differentiation rather than i...

journal_title：Melanoma research

authors： Luo D,Chen H,Searles G,Jimbow K

更新日期：1995-10-01 00:00:00